2009P PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients

Category Primary study
JournalAnnals of Oncology
Year 2024
This article has no abstract
Epistemonikos ID: fb27546963a2f1ab85e1a91813dbf0af23bab4cc
First added on: Feb 19, 2025